Skip to main content
NRXP
NASDAQ Life Sciences

NRX Pharmaceuticals Closes $22.3M Public Offering at Discount, Including Full Underwriter Option Exercise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$4.001
Mkt Cap
$146.727M
52W Low
$1.62
52W High
$5.055
52W Position info
147% above low
Off High info
21% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

NRXP has more than doubled off its 52-week low of $1.62.

Summary

NRX Pharmaceuticals closed a $22.3 million public offering, including the full exercise of the underwriters' option, providing crucial capital for operations despite significant dilution.


Key Events · Financing and Capital Events · NRXP

  • Public Offering Closed

    NRX Pharmaceuticals completed a public offering of 6,571,428 shares (including the full exercise of the underwriters' option) at $3.50 per share.

  • Significant Capital Raise

    The offering generated gross proceeds of approximately $22.3 million, providing essential funding for working capital and general corporate purposes.

  • Dilution at a Discount

    The shares were sold at $3.50, a discount to the current market price of $4.00, resulting in substantial dilution for existing shareholders.

  • Addressing Going Concern

    This capital raise is critical for the company, which recently disclosed a 'going concern' warning and increased cash burn in its Q1 2026 earnings report.


Analysis · NRXP · Life Sciences

This filing announces the closing of a significant public offering, including the full exercise of the underwriters' option, raising $22.3 million. While dilutive for existing shareholders, this capital infusion is critical for NRX Pharmaceuticals, which recently reported a 'going concern' warning and increased cash burn. The funds are earmarked for working capital and general corporate purposes, providing a necessary financial runway for the clinical-stage biopharmaceutical company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NRXP was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.7M. The 52-week trading range was $1.62 to $5.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NRXP - Latest Insights

NRXP
Nov 17, 2026, 7:18 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.10
Real-time Price: $2.73 info
Change: +$0.630 (+30%) info
Market Cap: $120.794M info
NRXP
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $2.73 info
Change: -$0.2498 (-8%) info
Market Cap: $120.794M info
NRXP
Oct 15, 2026, 8:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $2.73 info
Change: +$0.180 (+7%) info
Market Cap: $120.794M info
NRXP
Oct 05, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.86
Real-time Price: $2.73 info
Change: -$0.130 (-5%) info
Market Cap: $120.794M info
NRXP
Sep 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.98
Real-time Price: $2.73 info
Change: -$0.2545 (-9%) info
Market Cap: $120.794M info